Abstract
Bronchodilatation data from three, four-period cross-over studies were combined to assess the effect of oral terfenadine 60, 120, 180 mg and placebo on the airways of 26 patients with atopic asthma. Meta-analysis of these data showed that mean changes in FEV1 from pre-dose to 4 hr were 11.4, 14.6 and 11.8% for the three doses of terfenadine, respectively, and -2.9% for placebo. There was a significant treatment effect (P = 0.0001) but no effect of dose. Terfenadine, a non-sedating histamine H1-receptor antagonist, caused bronchodilatation in a single dose. Whether this effect is sustained with long-term treatment requires further investigation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
